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Only 20% of patients with chronic hepatitis C (CHC) 
progress to cirrhosis (1). Progressive fibrosis is the hall-
mark of an unfavorable course and is related to several 
factors such as male gender, contracting the disease at 
an older age, features of the metabolic syndrome, iron 
overload, ethanol abuse, and co-infection with hepatitis 
B or human acquired immunodeficiency viruses. How-
ever, the course of the disease is highly variable from 
individual to individual. Liver biopsy remains the gold 
standard for evaluating necroinflammation (grade) and 
fibrosis (stage) in CHC (2); however, this pre-eminence is 
currently being examined due to its intrinsic risks and 
limitations. Liver biopsy is an invasive procedure that 
carries a risk of complications, although rarely severe. 
The biopsy provides a very small specimen of liver tissue 
and has both a significant rate of sampling error, espe-
cially when the cylinder obtained is less than 25 mm in 
length, and interobserver variability. The risk-benefit ra-
tio of liver biopsy is insufficient to maintain it as a first-
line procedure, and new and non-invasive criteria for the 
evaluation of liver fibrosis are urgently needed (3).
A discussion on the molecular pathobiology of liver 
fibrogenesis is beyond the scope of this article (for a re-
view see references (4) and (5). The ideal marker for liver 
fibrosis must be specific to fibrosis of the liver, not in-
fluenced by co-morbidities, sensitive, reproducible, and 
informative for both the current stage of fibrosis as well 
as the rate of fibrogenesis activity (6). For practical pur-
poses, non-invasive fibrosis markers can be classified as 
direct (Class I biomarkers), indirect (Class II biomarkers), 
and imaging methods (7).
1.  Classifications  of  Noninvasive  Fibrosis 
Markers
1.1. Class I biomarkers 
These reflect the greater deposition of extracellular ma-
trix in the liver due to either increased synthesis by acti-
vated stellate cells (ASC) or slow removal by Kupffer and 
endothelial sinusoidal cells. They translate to an imbal-
ance between the synthesis and degradation of collagen, 
but they do not reflect the current stage of fibrosis. Many 
of these substances are collagen components or by-prod-
ucts, extracellular matrix-related enzymes, glycoproteins 
and matrix metalloproteinases, or glycosaminoglycans. 
However, this category also includes some growth factors 
such as transforming growth factor β (TGFβ) and connec-
tive tissue growth factor (4). The cost and complexity of 
  c 2011 Kowsar M.P.Co. All rights reserved.Hepat Mon. 2011;11(9):698-700
699 Noninvasive Liver Fibrosis in Chronic Hepatitis C Ladero JM
these determinations and their relatively low specificity 
and sensitivity greatly reduce their clinical usefulness. 
This has been the case for type I, III, and IV procollagens 
and for most enzymes involved in the synthesis and deg-
radation of extracellular matrix. However, 3 possible can-
didates for clinical use can be cited:
a)  Hyaluronic  acid  (HA):  Plasma  levels  of  this  gly-
cosaminoglycan,  which  is  synthesized  by  HSC  and  de-
graded by liver sinusoidal cells, are increased in CHC due 
to delayed degradation, and correlate with the stage of 
fibrosis (8). Its main value is to exclude advanced fibro-
sis or cirrhosis; however, it losses much of its usefulness 
in distinguishing among earlier stages of fibrosis. It has 
been proposed as a component of some scoring indexes, 
as discussed under class II biomarkers.
b) Glycoprotein YKL-40 (chondrex) is a fibroblast and 
endothelial growth factor that belongs to the chitinase 
family. YKL-40 has shown good specificity (81%) and sen-
sitivity (78%) for distinguishing between low-null (F0-F1) 
and significant (F2-F4) fibrosis in CHC. However, YKL-40 
is not liver-specific and may be elevated in extrahepatic 
diseases, such as arthritis (9).
c) Connective tissue growth factor (CTGF, CCN2) is syn-
thesized by activated HSC and hepatocytes under differ-
ential stimulus by TGFβ and is up-regulated in the earlier 
and intermediate stages of collagen synthesis, but de-
creases (as does its main stimulus, TGFβ) when cirrhosis 
is established. Therefore, CTGF could be a good marker of 
ongoing fibrogenesis, but not of cirrhosis (4).
1.2. Class II biomarkers
 They are empirically defined combinations of biochem-
ical tests (and sometimes platelet counts) reflecting liver 
changes that are induced, at least is part, by fibrosis, but 
are not directly related to the mechanisms of fibrogene-
sis. The obligate gold standard in the histological staging 
of fibrosis and the passport to their existence beyond the 
original report is a confirmed satisfactory AUROC (area 
under receiver operator curve) in independent studies. 
Single data, such as low a platelet count, high GGT plas-
ma level, or a GOT/GPT quotient > 1, are well known as sur-
rogate markers of advanced liver disease and thus of sig-
nificant or severe fibrosis. In a recent review of 9 scoring 
methods (10), we have not found substantial advantages 
among the most efficient ones (APRI, GUCI, King’s, and 
FIB-4). In fact, the most well known and easier to calcu-
late method, APRI, is not worse than the newer and more 
complex King’s score. At least in our experience, Forns’ 
score is the most sensitive for distinguishing between in-
termediate stages of fibrosis. Our personal contribution 
to this field was the finding that when added to APRI and 
King’s  scores,  serum  ferritin  concentration  improved 
the accuracy for detecting null-low fibrosis, and thus re-
duced the need to perform a liver biopsy. However, this 
feature needs independent confirmation.
Other more sophisticated and expensive methods are 
those that include in their formulas data that are not 
available  as  standard  laboratory  tests.  The  most  well 
known in this category is Fibrotest (Fibrosure in the 
USA), a commercially available test that is calculated by 
centrally introducing into its equation values for hapto-
globin,  α2-macroglobulin,  apolipoprotein  A1,  GGT,  and 
bilirubin. Fibrotest promoters (11), as well as several inde-
pendent studies, claim that Fibrotest is better than APRI 
for determining the intermediate stages of fibrosis; how-
ever, it loses part of its efficacy in patients with normal 
aminotransferase levels (7). Other scoring methods that 
include non conventional parameters are the ELF score 
(PIIINP, hyaluronic acid, and TIMP-1) (12) and FIBROSpect 
II,  Fibrometer,  and  Hepascore,  which  include  several 
class I biomarkers, but still have unproven superiority 
over the simpler scores, such as APRI (5).
It has been proposed that the combination or the se-
quential use of several scoring systems, in association 
with Fibroscan, if necessary (see later), could improve 
their diagnostic accuracy. Several sequential algorithms 
that combine APRI, Forns’ index, and Fibrotest provide 
high specificity in detecting F0-F1 fibrosis or cirrhosis, 
depending on the cut-off points selected, thus reducing 
the need to perform liver biopsies in a substantial pro-
portion of patients (6).
1.3. Imaging tests 
Ultrasonography  (US):  Several  features  of  ultrasonog-
raphy provided by standard US studies, such as portal ve-
nous flow and portal flow velocity, may be useful for the di-
agnosis of established cirrhosis. However, they are unable 
to discriminate between less advanced stages of fibrosis 
with a minimum precision, and it is usual to obtain a nor-
mal US study in a patient with advanced fibrosis.
Transient elastography (FibroScan): Fibrosis increas-
es hepatic rigidity and this method provides a measure 
of hepatic stiffness that is roughly proportional to the 
stage of cirrhosis. FibroScan is innocuous and easy to 
perform. It evaluates a virtual section of the liver that is 
much greater than the minimal cylinder provided by the 
needle biopsy (thus reducing the risk of sampling error), 
and  better  accuracy  than  several  scoring  systems  has 
been shown in most, if not all, published comparative 
studies.  However,  this  method  is  operator-dependent 
and has intrinsic technical limitations in both its perfor-
mance and adequate interpretation (i.e. narrow intercos-
tal spaces, obesity, or steatosis). FibroScan is an excellent 
tool when the clinical problem is to exclude cirrhosis (as 
are most of the scoring systems based on type II biomark-
ers); but, it losses sensitivity and specificity when the aim 
is to differentiate between less advanced stages of fibro-
sis (13). In spite of its wide acceptance among both phy-
sicians and patients, the clinical usefulness of transient 
elastography is far from firmly established, and it cannot 
be currently proposed as an alternative for liver biopsy 
in the detection of significant fibrosis (METAVIR ≥ F2), 
which is the main criterion used by most clinicians to 
make the decision for antiviral treatment (14).Hepat Mon. 2011;11(9):698-700
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Magnetic resonance imaging (MRI): Novel MRI appli-
cations have allowed for the detection of pathological 
abnormalities  in  liver  diseases.  The  sequential  admin-
istration of gadolinium and super magnetic iron oxide 
(SPIO) contrasts with adequate software analysis has pro-
vided highly valuable patterns of fibrosis compared with 
histopathological features (15). Preliminary results with 
diffusion-weighted MRI and MRI spectroscopy are prom-
ising, as are studies with MR Elastography. However, MRI 
equipment and performance are costly, uncomfortable 
for  patients,  and  time  consuming,  thus  reducing  the 
probability that MRI will have a significant role in liver 
fibrosis evaluation (16).
2. New developments
The search for new and more reliable non-invasive se-
rological biomarkers of liver fibrosis has found an excel-
lent allied in proteomics. Ho et al. (17) detected 3 putative 
biomarkers of fibrosis in chronic hepatitis C: α-2 mac-
roglobulin  (up-regulated),  vitamin  D  binding  protein 
(VDBP) (down-regulated), and apolipoprotein A1 (down-
regulated). In a recent study in our laboratory, we have 
confirmed the presence of low levels of VDBP (fraction 
3) in patients with hepatitis C and low stages of fibrosis 
when  compared  with  normal  controls  (manuscript  in 
preparation). Proteomic methods are continuously be-
ing improved (18), and it is to be expected that they will 
provide us with new and powerful markers of fibrosis 
not only in chronic hepatitis C, but in a wide range of 
chronic liver diseases.
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